8.55
-0.07(-0.81%)
Currency In USD
| Previous Close | 8.62 |
| Open | 8.63 |
| Day High | 8.68 |
| Day Low | 8.37 |
| 52-Week High | 9.76 |
| 52-Week Low | 4.2 |
| Volume | 321,197 |
| Average Volume | 538,674 |
| Market Cap | 467.51M |
| PE | -4.41 |
| EPS | -1.94 |
| Moving Average 50 Days | 7.7 |
| Moving Average 200 Days | 7.98 |
| Change | -0.07 |
If you invested $1000 in Zevra Therapeutics, Inc. (ZVRA) 10 years ago, it would be worth $41.3 as of June 01, 2025 at a share price of $8.55. Whereas If you bought $1000 worth of Zevra Therapeutics, Inc. (ZVRA) shares 5 years ago, it would be worth $2,857.62 as of June 01, 2025 at a share price of $8.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders
GlobeNewswire Inc.
May 29, 2025 8:35 PM GMT
Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company’s Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against Strategic Plan CELEBRATION, Fla., May 29, 2025 (G
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees
GlobeNewswire Inc.
May 21, 2025 11:30 AM GMT
ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors’ Recommendation and Vote “FOR” Wendy L. Dixon, Ph.D. and Tamara A. Favorito on th
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
GlobeNewswire Inc.
May 06, 2025 11:30 AM GMT
Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025CELEBRATION, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapi